ATTORNEY DOCKET NO.: 47236-0010-00-US (230845)

Application No.: 10/591,329

Response to Office Action mailed: March 17, 2010

Response dated: June 15, 2010

Page 2

AMENDMENTS TO THE SPECIFICATION

Applicants amend the Specification as follows:

Replace the paragraph bridging page 10-11 with the following:

At least one of C-C double bonds in a LCPUFA molecule may be conjugated, and the LCPUFA preferably includes arachidonic acid and/or docosahexaenoic acid. It is preferable that a proportion of arachidonic acid with respect to total fatty acids contained as constituents of total LCPUFA-PL is [[5]] <u>0.3</u> percent by weight or greater.

Replace the first full paragraph on page 11 with the following:

Specifically, the LCPUFA-PL is preferably at least one kind of glycerophospholipid selected from the group consisting of: phosphatidylcholine; phosphatidylserine; phosphatidylethanolamine; phosphatidylinositol; phosphatidic acid; and cardiolipin. In the case where the LCPUFA-PL is at least phosphatidylcholine, it is preferable that a proportion of arachidonic acid with respect to total fatty acids contained as constituents of total phosphatidylcholine be 15 percent by weight or greater. In the case where the LCPUFA-PL is at least phosphatidylserine, it is preferable that a proportion of arachidonic acid with respect to total fatty acids contained as constituents of total phosphatidylserine be [[20]] 5 percent by weight or greater.